With TCT in full swing, Or Yehuda, Israel-based Cardiovalve is launching the AHEAD US Multicenter Study, and jumping head first into the quickly growing TMVR market.
LivaNova is launching a pivotal study that will look at how stimulation of the vagus nerve with the VITARIA device can help treat heart failure patients.
Medtronic also received FDA approval for revised TAVR labeling that marks a critical moment for treating patients with bicuspid severe aortic stenosis.
The Cupertino, CA-based company garnered a lot of attention for incorporating an ECG into the next iteration of the Apple Watch and now analysts along with industry experts are sounding off on the technology’s potential impact.
Lake Oswego, OR-based Biotronik faces fierce competition from Medtronic, Boston Scientific, and Abbott in the cardiology space, but said its unique technology gives it an advantage.
As renal denervation procedures are making a comeback in treating resistant hypertension, Vascular Dynamics is going a different route to tackle the condition, by developing a stent-like application that will give therapy to patients.
With all of the indications Avinger is pursuing, it seems as if the Redwood City, CA-based company has an ‘infinite’ number of approaches in treating peripheral arterial disease patients.
The Mason, OH-based company said it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial.
The Flagstaff, AZ-based company received the green light to market the Molding and Occlusion Balloon in the U.S., Japan, and Europe.
After favorable feasibility study results, Medtronic is beginning a pilot study of the Extravascular Implantable Cardioverter Defibrillator system.
Boston Scientific has had a tough time catching up to peers in the transcatheter aortic valve replacement (TAVR) market, but the company's latest news about the Lotus valve has been well received by investors.
Some of medtech’s largest companies are working for approval in the TMVR space, which could one day rival or surpass TAVR.